Canaccord raised the firm’s price target on AxoGen (AXGN) to $27 from $24 and keeps a Buy rating on the shares. The fim said posted yet another strong Q as the company saw traction across its portfolio, growing over 23%, significantly above consensus expectations, and raising guidance to over 19% growth for the FY25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN: